BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 8873840)

  • 1. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
    Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
    Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
    Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
    Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Information provided by pharmacists regarding the effective timing of the coadministration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer - the second report].
    Nomura H; Kawakami H; Usui H; Suzuki S; Imoto S; Saito S
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1129-33. PubMed ID: 25248897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
    Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
    Ishida T; Kusaba T; Hayakawa H
    Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
    Hebbar M; Hecquet B; Vanlemmens L; Lecomte S; Pion JM; Adenis A; Bonneterre J
    Bull Cancer; 1995 Jan; 82(1):67-9. PubMed ID: 7742620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral treatment with ondansetron in an outpatient setting.
    Dicato MA
    Eur J Cancer; 1991; 27 Suppl 1():S18-9; discussion S22. PubMed ID: 1831630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.